LEBANON, N.H., Aug. 12, 2024 /PRNewswire/ -- Bio X Cell, LLC (BXC), a specialized provider of monoclonal antibodies for preclinical research applications, today announced the appointment of Christopher Conway as Chief Executive Officer. Conway brings more than 20 years of business experience spanning the aerospace, pharmaceutical/biotech, and contract research sectors.

"Chris not only brings strong business credentials, but understanding and respect for Bio X Cell's culture and mission to advance scientific discovery," stated Klaus Lubbe, founder of Bio X Cell. "His track record of driving profitable growth and operational excellence, while building strong, engaged teams, will help BXC deliver on its strategic plan for the future."

Conway previously served as President, R&D at Curia (formerly AMRI), where he managed the P&L for twenty global sites spanning small molecule chemistry, biologics, and analytical services. He began at AMRI/Curia in 2008 in commercial roles and was promoted to Senior Vice President in 2015 and President, R&D in 2019. Prior to joining AMRI, Conway held leadership positions with Johnson & Johnson and Dynabil Industries.

"Chris' experience transitioning businesses from founder-led to private equity ownership makes him uniquely qualified to lead BXC through the next phase of growth," said Craig Majernik, Managing Director at Windjammer Capital Investors, the private equity firm that partnered with Bio X Cell in June 2023.

"I am honored to have the opportunity to lead Bio X Cell," said Conway. "I am impressed by the company's commitment to providing innovative products and best-in-class service to the research community. I look forward to working with the talented team at BXC to build on this strong foundation."

About Bio X Cell
Founded in 1997, Bio X Cell is a specialized provider of monoclonal antibodies for preclinical research applications. The company's portfolio includes more than 400 functional grade antibodies used by over 1,500 academic, government, and commercial customers in more than 50 countries. Bio X Cell antibodies have been cited in more than 20,000 research publications. For more information, visit https://bioxcell.com/

CONTACT:
Connor Halverson
That's Nice LLC
+1 212 366 4455
connor@thatsnice.com
